The estimated Net Worth of Vijay K Iyengar is at least $7.66 Milion dollars as of 25 July 2024. Dr Iyengar owns over 15,571 units of Incyte stock worth over $2,316,934 and over the last 9 years he sold INCY stock worth over $4,393,550. In addition, he makes $945,900 as Exec. VP of Global Strategy & Corp. Devel. at Incyte.
Sign up
Dr D INCY stock SEC Form 4 insiders trading
Dr has made over 13 trades of the Incyte stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 15,571 units of INCY stock worth $1,089,970 on 25 July 2024.
The largest trade he's ever made was selling 17,324 units of Incyte stock on 23 December 2022 worth over $1,399,779. On average, Dr trades about 2,006 units every 58 days since 2016. As of 25 July 2024 he still owns at least 36,701 units of Incyte stock.
You can see the complete history of Dr Iyengar stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Vijay K. Iyengar M.D. biography
Dr. Vijay K. Iyengar M.D. is the Exec. VP of Global Strategy & Corp. Devel. at Incyte.
What is the salary of Dr D?
As the Exec. VP of Global Strategy & Corp. Devel. of Incyte, the total compensation of Dr D at Incyte is $945,900. There are 10 executives at Incyte getting paid more, with Herve Hoppenot having the highest compensation of $15,151,200.
How old is Dr D?
Dr D is 48, he's been the Exec. VP of Global Strategy & Corp. Devel. of Incyte since . There are 24 older and 2 younger executives at Incyte. The oldest executive at Incyte Corp. is Pamela M. Murphy, 70, who is the VP of Investor Relations & Corp. Communications.
What's Dr D's mailing address?
Vijay's mailing address filed with the SEC is 1801 AUGUSTINE CUT-OFF, , WILMINGTON, DE, 19803.
Insiders trading at Incyte
Over the last 21 years, insiders at Incyte have traded over $114,417,378 worth of Incyte stock and bought 24,211,970 units worth $713,884,116 . The most active insiders traders include Bros. Advisors Lp14159, L.P..., Bros. Advisors Lp667, L.P.B... a Brothers Life Sciences Capi.... On average, Incyte executives and independent directors trade stock every 14 days with the average trade being worth of $4,355,654. The most recent stock trade was executed by Steven H Stein on 12 August 2024, trading 11,608 units of INCY stock currently worth $703,793.
What does Incyte do?
incyte is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology. our vision is to become a leader in the development and delivery of novel drugs for serious unmet medical needs. we have established multiple collaborations with major pharmaceutical companies to support the clinical development and global commercialization of several of our compounds. the incyte corporate headquarters is located in wilmington, delaware, and more than 625 employees comprise our experienced management, discovery, clinical development and commercial teams. our assets, experience and prior success in bringing important new drugs to market put us in a strong position to make a difference by improving the lives of patients and building sustainable value for our shareholders. for more information about incyte, please visit our corporate website at www.incyte.com.
What does Incyte's logo look like?
Complete history of Dr Iyengar stock trades at Incyte
Incyte executives and stock owners
Incyte executives and other stock owners filed with the SEC include:
-
Herve Hoppenot,
Chairman of the Board, President, Chief Executive Officer -
Steven Stein,
Executive Vice President, Chief Medical Officer -
Wenqing Yao,
Executive Vice President, Head of Discovery Chemistry -
Barry Flannelly,
Executive Vice President and General Manager - US -
Christiana Stamoulis,
Chief Financial Officer, Executive Vice President -
Maria Pasquale,
Executive Vice President, General Counsel -
Herve Hoppenot,
Chairman, Pres & CEO -
Paula Swain,
Executive Vice President - Human Resources -
Christiana Stamoulis,
Exec. VP & CFO -
Dr. Steven H. Stein,
Exec. VP & Chief Medical Officer -
Dr. Vijay K. Iyengar M.D.,
Exec. VP of Global Strategy & Corp. Devel. -
Dr. Barry P. Flannelly M.B.A., MBA, Pharm.D.,
Exec. VP & GM of North America -
Dr. Barry P. Flannelly M.B.A., Pharm.D., MBA,
Exec. VP & GM of North America -
Julian Baker,
Lead Independent Director -
Paul Clancy,
Independent Director -
Wendy Dixon,
Independent Director -
Jacqualyn Fouse,
Independent Director -
Jean-Jacques Bienaime,
Independent Director -
Paul Friedman,
Independent Director -
Edmund Harrigan,
Independent Director -
Michael Booth,
Vice President - Investor Relations -
Katherine High,
Independent Director -
Vijay Iyengar,
Executive Vice President, Global Strategy and Corporate Development -
Dashyant Dhanak,
Executive Vice President, Chief Scientific Officer -
Thomas Tray,
VP of Fin., Chief Accounting Officer & Controller -
Pamela M. Murphy,
VP of Investor Relations & Corp. Communications -
Maria E. Pasquale,
Exec. VP & Gen. Counsel -
Christine Chiou,
Head of Investor Relations -
Dr. Dashyant Dhanak Ph.D.,
Exec. VP & Chief Scientific Officer -
Michael James Morrissey,
Exec. VP & Head of Global Technical Operations -
Reid M Huber,
EVP, Chief Scientific Officer -
Julian14159, L.P.667, L.P.B...,
-
David W Gryska,
Executive Vice President, CFO -
Paul Trower,
Principal Accounting Officer -
Julianbaker Felixbaker Bros...,
-
Eric H. Siegel,
EVP, General Counsel -
Paul A Brooke,
Director -
Matteo Trotta,
EVP, GM, Dermatology US -
Bros. Advisors Lp14159, L.P...,
-
Bros. Advisors Lp Baker Bro...,
-
Bros. Capital (Gp), Llcbake...,
-
Schutter Richard U De,
Director -
Barry A Ariko,
Director -
Foundation Inc Damial,
10% owner -
Daniel R Tisch,
10% owner -
Julian Baker,
Director -
Biotech Capital Ii Gp Llcba...,
-
James M Daly,
Exec. VP & Chief Comm. Officer -
Brothers Life Sciences Capi...,
-
Laurent Chardonnet,
VP Finance and Treasurer -
John A Keller,
Exec VP & Chief Bus Officer -
Jon S Saxe,
Director -
Biotech Capital (Gp), Llcba...,
-
/ Tisch Capital (Gp), Llcba...,
-
Brothers Life Sciences Capi...,
-
John F Niblack,
Director -
Biotech Capital (Gp), Llcba...,
-
Fred B Craves,
Director -
Biotech Capital Gp Llcbaker...,
-
David C Hastings,
Exec VP & CFO -
Patricia A Schreck,
EVP and General Counsel -
/ Tisch Capital (Gp), Llcba...,
-
Richard S Levy,
EVP, Chief Drug Dev&Medical Of -
Biotech Capital (Gp), Llcba...,
-
Scott W Hurley,
-
Capital (Gp), Llcbaker Feli...,
-
Matthew Emmens,
Director -
/ Tisch Capital (Gp), Llcba...,
-
Capital (Gp), Llcbaker Juli...,
-
Steven M. Friedman,
EVP, Biology & Preclinical Dev -
Bros. Capital (Gp), Llcbake...,
-
Julianbaker Felixbaker Bros...,
-
James S Tisch,
10% owner -
Bros. Capital (Gp), Llcbake...,
-
Brian W Metcalf,
-
Andrew H Tisch,
10% owner -
Michael James Morrissey,
EVP, Head of Tech. Operations -
Thomas J Tisch,
10% owner -
Roy A Whitfield,
Director -
Capital (Gp), Llcbaker Juli...,
-
Biotech Capital Ii Gp Llcba...,
-
Brothers Life Sciences Capi...,
-
Bonnie J Tisch,
10% owner -
Bros. Advisors Lp667, L.P.B...,
-
Jonathan Elliott Dickinson,
EVP, General Manager, Europe -
Bros. Advisors Lp Baker Bro...,
-
Thomas Tray,
Principal Accounting Officer -
Otis W Brawley,
Director -
Bros. Advisors Lp667, L.P.B...,
-
Pablo J Cagnoni,
President, R&D -
Susanne Schaffert,
Director -
Sheila A. Denton,
EVP & General Counsel